WO2013146435A1 - 骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤 - Google Patents
骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤 Download PDFInfo
- Publication number
- WO2013146435A1 WO2013146435A1 PCT/JP2013/057706 JP2013057706W WO2013146435A1 WO 2013146435 A1 WO2013146435 A1 WO 2013146435A1 JP 2013057706 W JP2013057706 W JP 2013057706W WO 2013146435 A1 WO2013146435 A1 WO 2013146435A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- giant cell
- bone
- cell tumor
- chondrosarcoma
- pparγ
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to a preventive or therapeutic agent for giant cell tumors or chondrosarcoma that occurs in bones and soft parts using a non-steroidal anti-inflammatory agent or a thiazolidine derivative.
- the present invention also relates to a screening method for selecting a substance that induces and expresses PPAR ⁇ and thereby induces apoptosis or adipocyte differentiation as a preventive or therapeutic agent for giant cell tumors or chondrosarcoma that develop in bone and soft parts.
- Giant cell tumor of the bone is a benign tumor that frequently occurs around young and middle-aged knee joints, and the male-to-female ratio is 1: 1.3 to 1.5, and the prevalence of women is high. In addition, it accounts for about 5% of all bone tumors and about 20% of benign bone tumors. Although it is a benign tumor, it has a high recurrence rate of 10-30%, and sometimes due to lung metastasis or malignant transformation. It may be difficult to treat.
- the pathological findings are mainly multinucleated giant cells and monocytic cells, with spindle cells in between.
- the main body of the tumor is not a multinucleated giant cell, but a fibroblast-like spindle-shaped cell present in the stroma.
- Tendon sheath giant cell tumor is a neoplastic disease arising from the synovium of the tendon sheath, joint, and bursa. Based on the growth type of the lesion, it is classified into localized type and diffuse type.
- tendon sheath giant cell tumor is synonymous with tendon sheath giant cell tumor
- diffuse type tendon sheath giant cell tumor is synonymous with pigmented chorio-nodal synovitis.
- Tendon sheath giant cell tumors are common in women in their 30s and 50s. About 85% occur in the vicinity of the joints of the fingers and on the flexor tendons, and then in the footpads. It may infiltrate into the bone.
- Pathological findings are mainly oval to spindle-shaped histiocytic mononuclear cells, with hemosiderin deposition on multinucleated giant cells and foam cells.
- Treatment is tumor resection (simple excision) according to benign tumors, but a recurrence rate of 4-30% has been reported.
- Pigmented chorio-nodular synovitis is relatively common among young women under 40 years of age, with the highest number of knee joints, and also occurs in hips, legs, elbows, and shoulder joints. Synovial villus and nodule-like growth in the joint, arthremia is often observed, and it also infiltrates into the bone, resulting in secondary osteoarthritis.
- Pathological findings include synovial cell-like mononuclear cells, multinucleated giant cells, foam cells, hemosiderin phagocytic cells, and inflammatory cells.
- the tumor is removed by surgery, but complete resection is difficult, and the recurrence rate is as high as 40-50%.
- Chondrosarcoma accounts for about 20% of primary malignant bone tumors and is the most frequent after osteosarcoma. Histologically, it is classified into normal chondrosarcoma, periosteal chondrosarcoma, mesenchymal chondrosarcoma, dedifferentiated chondrosarcoma, clear cell chondrosarcoma, extraskeletal mucinous chondrosarcoma, and the like.
- the normal type is common in the 30s and 50s and is slightly more common among men. It occurs most frequently in the pelvis bone, followed by the radius, proximal femur, proximal humerus, and distal femur.
- Mesenchymal chondrosarcoma is more common in younger teens and thirties than normal chondrosarcoma, and is more common in the jawbone, spine, iliac bone, ribs, and femur.
- Dedifferentiated chondrosarcoma is a low-malignant normal chondrosarcoma that results in a non-cartilaginous high malignant tumor, which are adjacent to each other with a clear boundary.
- Peroxisome Proliferator-Activated Receptor ⁇ is a protein belonging to the nuclear receptor superfamily and also functions as a transcription factor.
- PPAR ⁇ peroxisome proliferator-responsive receptor ⁇
- PPAR ⁇ is mainly distributed in adipose tissue and is involved in adipocyte differentiation and is also expressed in macrophages and vascular endothelial cells, but other actions include anti-diabetic action, anti-arteriosclerosis action, bone metabolism, It has been reported to have antitumor and anti-inflammatory effects.
- Non-Patent Documents 1 and 2 For example, PPAR ⁇ activation has been reported to cause apoptosis in various tumors (Non-Patent Documents 1 and 2), breast cancer (Non-Patent Document 3), colon cancer (Non-Patent Document 4), and lung cancer (Non-Patent Documents). It has been confirmed that PPAR ⁇ is expressed in various cancer cells such as literature 5). In addition, it has been reported that the activation of PPAR ⁇ is induced not only by PPAR ⁇ ligand but also by non-steroidal anti-inflammatory agents and induces cell death (Non-patent Document 6).
- a further object of the present invention is a screening method for selecting a substance that induces and expresses PPAR ⁇ and thereby induces apoptosis or adipocyte differentiation as a preventive or therapeutic agent for giant cell tumor or chondrosarcoma that develops in bone and soft part. Is to provide.
- PPAR ⁇ is usually not expressed in giant cell tumors or chondrosarcoma that develop in bone and soft parts.
- PPAR ⁇ is expressed in bone giant cell tumors, which are one of non-steroidal anti-inflammatory agents and are giant cell tumors that occur in bone and soft parts administered with zaltoprofen having PPAR ⁇ agonist activity. It was confirmed that apoptosis and differentiation into adipocytes were induced. As a result of further studies based on these findings, the present inventors have completed the present invention.
- the present invention [1] A preventive or therapeutic agent for giant cell tumors or chondrosarcoma that occurs in bone and soft parts, containing a nonsteroidal anti-inflammatory agent or a thiazolidine derivative as an active ingredient; [2] The prophylactic or therapeutic agent according to the above [1], wherein the nonsteroidal anti-inflammatory agent is selected from the group consisting of zaltoprofen, diclofenac, indomethacin, oxaprozin, acetaminophen and ketoprofen; [3] The prophylactic or therapeutic agent according to the above [1], wherein the thiazolidine derivative is selected from the group consisting of troglitazone, rosiglitazone, pioglitazone, valaglitazone, and riboglitazone; [4] The above-mentioned [1] to [3], wherein the giant cell tumor occurring in the bone / soft part is selected from the group consisting of a giant cell tumor of the bone,
- the prophylactic or therapeutic agent of the present invention for giant cell tumors or chondrosarcoma patients that develop in bone and soft tissue, as chemotherapeutic agents before or after surgery, or giant cells that develop in bone and soft tissue It can be administered as a prophylactic agent to those who are likely to develop sexual tumors or chondrosarcoma. Further, according to the present invention, by selecting PPAR ⁇ and a test substance that controls apoptosis or adipocyte differentiation, it is possible to search for a novel preventive or therapeutic agent for giant cell tumor or chondrosarcoma that occurs in bone and soft parts. It becomes.
- the inventors have found that PPAR ⁇ is not expressed in cells derived from patients with giant cell tumors that develop in bones and soft parts, and that giant cells that have a specific activity having PPAR ⁇ agonist activity occur in bones and soft parts. It was discovered that PPAR ⁇ expression was induced in tumors, and at the same time, apoptosis or adipocyte differentiation was induced. Therefore, the present invention is able to induce PPAR ⁇ -mediated apoptosis or adipocyte differentiation in a giant cell tumor that develops in the bone / soft part by the PPAR ⁇ expression-inducing activity and PPAR ⁇ agonistic activity. Prophylactic or therapeutic agents are provided. The present invention also provides a prophylactic or therapeutic agent for chondrosarcoma that can induce PPAR ⁇ -mediated apoptosis or adipocyte differentiation by PPAR ⁇ expression-inducing activity and PPAR ⁇ agonistic activity.
- the giant cell tumor occurring in the bone / soft part to which the preventive or therapeutic agent of the present invention can be applied is not particularly limited as long as the giant cell occurring in the bone / soft part is observed.
- it can be preferably applied to tumors that generate giant cells around bones, joints, and tendon sheaths.
- tumors include giant cell tumor of bone, giant cell tumor of tendon sheath, and pigmented chorionodular synovitis.
- Examples of other benign giant cell tumors that occur in bones and soft parts include chondroblastoma, non-ossifying fibroma, osteoblastoma, aneurysmal bone cyst.
- chondrosarcoma to which the preventive or therapeutic agent of the present invention can be applied normal chondrosarcoma, periosteal chondrosarcoma, mesenchymal chondrosarcoma, dedifferentiated chondrosarcoma, clear cell chondrosarcoma, extraosseous mucus Type chondrosarcoma.
- the preventive or therapeutic agent of the present invention can also be used for tumors in which PPAR ⁇ expression is observed.
- tumors that have PPAR ⁇ expression include breast cancer, colon cancer, lung cancer, thyroid cancer, esophageal cancer, stomach cancer, pancreatic cancer, liver cancer, kidney cancer, bladder cancer, ovarian cancer, cervical cancer, prostate cancer, malignant melanoma, Examples include leukemia, malignant lymphoma, liposarcoma, leiomyosarcoma, and osteosarcoma.
- PPAR ⁇ is a protein belonging to the nuclear receptor superfamily, and recognizes the PPAR response region (PPRE) by forming a heterodimer with the retinoid X receptor (RXR), which is one of the nuclear receptors. And activates transcription of downstream genes.
- PPRE PPAR response region
- RXR retinoid X receptor
- examples of the substance having PPAR ⁇ expression-inducing activity and having PPAR ⁇ agonistic activity include non-steroidal anti-inflammatory agents. Therefore, PPAR ⁇ expression-inducing activity and PPAR ⁇ agonistic activity can induce PPAR ⁇ -mediated apoptosis or adipocyte differentiation in giant cell tumors or chondrosarcomas that develop in bone and soft parts, or giant cell tumors that occur in bones and soft parts or
- the prophylactic or therapeutic agent for chondrosarcoma is a prophylactic or therapeutic agent for giant cell tumors or chondrosarcoma that occur in bones and soft parts, containing a nonsteroidal anti-inflammatory agent as an active ingredient.
- the non-steroidal anti-inflammatory agent is not particularly limited as long as it is a compound that inhibits the synthesis of prostaglandins and thromboxanes by inhibiting cyclooxygenase and exhibits an anti-inflammatory action.
- zaltoprofen, diclofenac, indomethacin Oxaprozin, acetaminophen, ketoprofen and the like preferably zaltoprofen, diclofenac and indomethacin.
- other than non-steroidal anti-inflammatory agents for example, thiazolidine derivatives can be mentioned.
- PPAR ⁇ expression-inducing activity and PPAR ⁇ agonistic activity can induce PPAR ⁇ -mediated apoptosis or adipocyte differentiation in giant cell tumors or chondrosarcomas that develop in bone and soft parts, or giant cell tumors that occur in bones and soft parts or
- the prophylactic or therapeutic agent for chondrosarcoma is a prophylactic or therapeutic agent for giant cell tumor or chondrosarcoma that develops in bone and soft part, containing thiazolidine derivative as an active ingredient.
- Thiazolidine derivatives are known to activate PPAR ⁇ and are PPAR ⁇ agonists that promote transcription of the adiponectin gene. Examples of the thiazolidine derivative include troglitazone, rosiglitazone, pioglitazone, valaglitazone, and riboglitazone.
- the PPAR ⁇ expression-inducing activity of a substance having a PPAR ⁇ expression-inducing activity and a PPAR ⁇ agonistic activity, including a nonsteroidal anti-inflammatory agent or a thiazolidine derivative can be confirmed by a known method described later.
- a method of performing reverse transcription reaction and PCR using a primer capable of extracting mRNA from a giant cell tumor or chondrosarcoma that develops in bone / soft tissue by a normal method and amplifying a PPAR ⁇ transcript, -A giant cell tumor or chondrosarcoma that develops in the soft part can be fixed or cell debris extracted, and its expression confirmed by a technique using an antigen-antibody reaction using an antibody against the PPAR ⁇ translation product.
- the transcription product and translation product of PPAR ⁇ are publicly known.
- GenBank accession no. BC006811 discloses nucleotide sequence information
- GenBank accession no. AAH06811 discloses amino acid sequence information.
- the PPAR ⁇ agonistic activity can be confirmed, for example, by measuring the expression level of a downstream gene or the expression level of a lipid.
- downstream genes of PPAR ⁇ include apoptosis-related genes, adipocyte differentiation-related genes, arteriosclerosis-related genes, and anti-inflammatory-related genes.
- the apoptosis-related gene may be a gene responsible for an apoptosis signal or may be a marker gene for apoptosis.
- Examples of apoptosis-related genes include Caspase3 and p53. As a transcription product of Caspase3, GenBank accession No. The base sequence information is disclosed in BC016926, and the translation product is GenBank accession no.
- AAH16926 discloses amino acid sequence information. As a transcription product of p53, GenBank accession no. The base sequence information is disclosed in NM_000546, and the translation product is GenBank accession no. Amino acid sequence information is disclosed in NP_000537.
- the adipocyte differentiation-related gene may be a gene that induces differentiation into adipocytes, or a marker gene for adipocyte differentiation. Examples of the adipocyte differentiation-related genes include Setd8 (SET domain containing (lysine methyltransferase) 8), Setdb1 (SET domain, bifurcated1, LPL (Lipoprotein B), LPL (Lipoprotein B), LPL (Lipoprotein B).
- GenBank accession No. NM — 020382 discloses nucleotide sequence information
- the translation product is GenBank accession No.
- Amino acid sequence information is disclosed in NP — 065115.
- GenBank accession no. The base sequence information is disclosed in BC028671, and the translation product is GenBank accession no.
- AAH28671 discloses amino acid sequence information.
- GenBank accession no. The base sequence information is disclosed in BC011353, and the translation product is GenBank accession no. AAH11353 discloses amino acid sequence information.
- GenBank accession no. As a transcription product of Leptin, GenBank accession no. The base sequence information is disclosed in BC069452, and the translation product of GenBank accession no. AAH69452 discloses amino acid sequence information.
- GenBank accession no. BC003672 discloses nucleotide sequence information
- the translation product is GenBank accession no. AAH03672 discloses amino acid sequence information.
- Adiponectin transcripts include GenBank accession no.
- the base sequence information is disclosed in BC096308, and the translation product is GenBank accession no.
- AAH96308 discloses amino acid sequence information.
- BC002483 discloses nucleotide sequence information, and the translation product is GenBank accession no. AAH002483 discloses amino acid sequence information.
- Examples of the arteriosclerosis-related gene include AT1R (angiotensin II receptor I).
- AT1R angiotensin II receptor I
- GenBank accession no. BC068494 discloses nucleotide sequence information, and the translation product thereof is GenBank accession No. AAH68494 discloses amino acid sequence information.
- anti-inflammatory-related genes include NF- ⁇ B (nuclear factor kappa-light-chain-enhancer of activated B cells).
- NF- ⁇ B nuclear factor kappa-light-chain-enhancer of activated B cells.
- NM_003998 discloses base sequence information, and the translation product thereof is GenBank accession No. Amino acid sequence information is disclosed in NP_003989.
- the lipid is not particularly limited as long as it is a lipid contained in an adipocyte or tissue, and examples thereof include phospholipid, glycolipid, lipoprotein, neutral fat, ceramide and the like.
- RNA eg, total RNA, mRNA
- the RNA fraction can be prepared using a known method such as guanidine-CsCl ultracentrifugation or AGPC, but using a commercially available RNA extraction kit (eg, RNeasy Mini Kit; manufactured by QIAGEN, etc.) High-purity total RNA can be prepared quickly and easily from a small number of cells.
- RNA fraction As a means for detecting the transcription product of the gene in the RNA fraction, for example, a method using hybridization (Northern blot, dot blot, DNA chip analysis, etc.) or PCR (RT-PCR, competitive PCR, real-time PCR, etc.) ) And the like. Quantitative PCR methods such as competitive PCR and real-time PCR are preferred in that expression variation of the gene can be detected quickly and simply with high quantitativeness from a small amount of sample.
- the PPAR ⁇ gene can be detected using, for example, a nucleic acid probe that can specifically detect the transcription product of the gene.
- the nucleic acid probe used for measuring the PPAR ⁇ expression-inducing activity is about 15 bases or more, preferably about 18 to about 500 bases, more preferably about 18 to about 200 bases, more preferably about 18 to about 50 bases.
- the polynucleotide may be DNA or RNA, or may be a DNA / RNA chimera.
- DNA is used.
- the polynucleotide used as the probe may be double-stranded or single-stranded. In the case of a double strand, it may be a double-stranded DNA, a double-stranded RNA or a DNA: RNA hybrid. In the case of a single strand, an antisense strand can be used.
- the nucleic acid probe used for measuring the PPAR ⁇ expression-inducing activity is a polynucleotide containing a nucleotide sequence that hybridizes to a transcription product of the PPAR ⁇ gene under stringent conditions.
- Hybridization is performed according to a method known per se or a method analogous thereto, for example, the method described in Molecular Cloning, Second Edition (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989). Can do.
- stringent conditions for example, a hybridization reaction at 45 ° C. in 6 ⁇ SSC (sodium chloride / sodium citrate), followed by one or more times at 65 ° C. in 0.2 ⁇ SSC / 0.1% SDS Cleaning and the like.
- the nucleic acid functioning as a probe capable of detecting the expression of the PPAR ⁇ gene uses an individual primer (eg, human, monkey, mouse, rat, dog, etc.) using a primer set described later that can amplify a part or all of the transcription product of the gene.
- an individual primer eg, human, monkey, mouse, rat, dog, etc.
- a primer set described later that can amplify a part or all of the transcription product of the gene.
- any cell of bovine, horse, pig, sheep, goat, cat, rabbit, hamster, guinea pig, etc. preferably human [eg hepatocytes, splenocytes, neurons, glial cells, pancreatic ⁇ cells, bone marrow cells, mesangial cells Langerhans cells, epidermal cells, epithelial cells, goblet cells, endothelial cells, smooth muscle cells, fibroblasts, fibrocytes, muscle cells, adipocytes, immune cells (eg, macrophages, T cells, B cells, natural killer cells, Mast cells, neutrophils, basophils, eosinophils, monocytes), megakaryocytes, synoviocytes, chondrocytes, bone cells, osteoblasts, osteoclasts, mammary cells Or stromal cells, or precursor cells of these cells, stem cells, cancer cells, etc.] or any tissue in which these cells exist [eg, brain, brain regions (eg, olfactory
- nucleic acid is chemically synthesized using a commercially available DNA / RNA automatic synthesizer or the like based on the base sequence information of the PPAR ⁇ gene. Can also be obtained.
- a chip on which the nucleic acid is immobilized can be produced by directly synthesizing the nucleic acid in situ (on chip) on a solid phase such as silicon or glass.
- a nucleic acid functioning as a primer capable of amplifying a part or all of the transcription product of the PPAR ⁇ gene is a commercially available DNA based on the base sequence information of the PPAR ⁇ gene described above. / It can be obtained by chemically synthesizing using an automatic RNA synthesizer or the like.
- the nucleic acid is preferably labeled with a labeling agent in order to enable detection and quantification of the target nucleic acid.
- a labeling agent for example, a radioisotope, an enzyme, a fluorescent substance, a luminescent substance, or the like is used.
- the radioisotope for example, [ 32 P], [ 3 H], [ 14 C] and the like are used.
- the enzyme those which are stable and have high specific activity are preferable. For example, ⁇ -galactosidase, ⁇ -glucosidase, alkaline phosphatase, peroxidase, malate dehydrogenase and the like are used.
- fluorescent substance for example, fluorescamine, fluorescein isothiocyanate and the like are used.
- luminescent substance for example, luminol, luminol derivatives, luciferin, lucigenin and the like are used.
- biotin- (strept) avidin can also be used for binding between the probe and the labeling agent.
- the RNA fraction prepared as described above is separated by gel electrophoresis, then transferred to a membrane such as nitrocellulose, nylon, polyvinylidene difluoride, and prepared as described above.
- the amount of PPAR ⁇ gene expression can be measured by measuring the amount of label bound to the membrane for each band after specific hybridization in a hybridization buffer containing the labeled probe. it can.
- the expression level of the gene can be measured by subjecting the membrane spotted with the RNA fraction to a hybridization reaction in the same manner and measuring the amount of the label on the spot.
- cDNA in which an appropriate promoter such as T7 promoter is introduced is synthesized from the RNA fraction prepared as described above by reverse transcription, and further cRNA is synthesized using RNA polymerase (this)
- a labeled cRNA is obtained by using a mononucleotide labeled with biotin or the like as a substrate). It is possible to measure the expression level of the PPAR ⁇ gene by bringing this labeled cRNA into contact with the above-described probe on which the probe is immobilized and performing a hybridization reaction and measuring the amount of label bound to each probe on the solid phase. it can.
- a quantitative PCR method is used as a method for measuring the expression of the PPAR ⁇ gene.
- quantitative PCR include competitive PCR and real-time PCR.
- set of oligonucleotides used as primers in PCR include nucleic acid primers that can specifically detect the transcription product of the aforementioned PPAR ⁇ gene.
- the nucleic acid primer used in the test method of the present invention has about 15 bases or more, preferably about 15 to about 50 bases, more preferably about 15 to about 30 bases, and more preferably about 15 to about 30 bases.
- RT-PCR is a method in which a known amount of another template nucleic acid that can be amplified by a set of primers that can amplify a target DNA is allowed to coexist in a reaction solution as a competitor to cause an amplification reaction competitively.
- the competitor nucleic acid may be DNA or RNA.
- cDNA may be synthesized by reverse transcription reaction from the RNA fraction prepared as described above, and then PCR may be performed in the presence of the primer set and the competator.
- the competor is added to the RNA fraction. May be added to perform reverse transcription reaction, and the primer set may be further added to perform PCR. In the latter case, since the efficiency of the reverse transcription reaction is taken into consideration, the absolute amount of the original mRNA can be estimated.
- real-time PCR is a method for monitoring the amount of amplification in real time using a fluorescent reagent, and requires an apparatus in which a thermal cycler and a spectrofluorometer are integrated.
- a thermal cycler and a spectrofluorometer are integrated.
- Such devices are commercially available.
- a reagent that emits fluorescence by binding to the above primer set and double-stranded DNA such as SYBR Green I, ethidium bromide ( Intercalator), a nucleic acid that can be used as the probe (however, the nucleic acid hybridizes to the target nucleic acid in the amplification region) and a fluorescent substance (eg, FAM, HEX, TET, FITC, etc.) and a quencher (Example: TAMRA, DABCYL, etc.)
- a fluorescent reagent (probe) such as a modified one (TaqMan TM probe or Molecular Beacon probe) is added to the PCR reaction system.
- the intercalator binds to the synthesized double-stranded DNA and emits fluorescence when irradiated with excitation light, the amount of amplification product generated can be monitored by measuring the fluorescence intensity, thereby increasing the amount of original template cDNA. Can be estimated.
- TaqMan TM probe is an oligonucleotide that can be hybridized to the target nucleic acid amplification region, both ends modified with a fluorescent substance and a quenching substance, and hybridizes to the target nucleic acid during annealing, but does not emit fluorescence due to the presence of the quenching substance
- fluorescence is emitted by being decomposed by the exonuclease activity of DNA polymerase and releasing a fluorescent substance. Therefore, the amount of amplification product produced can be monitored by measuring the fluorescence intensity, thereby estimating the amount of the original template cDNA.
- the Molecular Beacon probe is an oligonucleotide that can be hybridized to the target nucleic acid amplification region and has a hairpin secondary structure, both ends of which are modified with a fluorescent substance and a quencher, and is quenched when it has a hairpin structure. Fluorescence is not emitted due to the presence of the substance, but is emitted when the distance between the fluorescent substance and the quenching substance is increased by hybridization to the target nucleic acid during annealing. Therefore, the amount of amplification product produced can be monitored by measuring the fluorescence intensity, thereby estimating the amount of the original template cDNA. Since real-time RT-PCR can monitor the amount of PCR amplification in real time, electrophoresis is not required and the expression of the PPAR ⁇ gene can be analyzed more quickly.
- the expression of the PPAR ⁇ gene in the cell can be examined by preparing a protein fraction from the cell and detecting the translation product (ie, PPAR ⁇ ) of the gene contained in the fraction.
- the detection of PPAR ⁇ can be performed by an immunoassay (eg, ELISA, FIA, RIA, Western blot, etc.) using an antibody that specifically recognizes the protein. It can also be performed by measuring using a known technique.
- the protein can also be detected using mass spectrometry such as MALDI-TOFMS.
- an antibody that specifically recognizes PPAR ⁇ is produced by an existing general production method using a polypeptide contained in the protein or a partial peptide having the antigenicity of the polypeptide or a partial peptide having a portion corresponding to an epitope as an immunogen. can do.
- the antibody includes a polyclonal antibody, a natural antibody such as a monoclonal antibody (mAb), a chimeric antibody that can be produced using a gene recombination technique, a humanized antibody or a single chain antibody, and binding properties thereof. Fragments are included, but are not limited to these.
- the antibody is a polyclonal antibody, a monoclonal antibody or a binding fragment thereof.
- the binding fragment means a partial region of the aforementioned antibody having specific binding activity, and specifically includes, for example, F (ab ′) 2 , Fab ′, Fab, Fv, sFv, dsFv, sdAb and the like. (Exp. Opin. Ther. Patents, Vol. 6, No. 5, p. 441-456, 1996).
- the class of the antibody is not particularly limited, and includes antibodies having any isotype such as IgG, IgM, IgA, IgD, or IgE. IgG or IgM is preferable, and IgG is more preferable in consideration of ease of purification.
- a PPAR ⁇ measurement system may be constructed by adding ordinary technical considerations to those skilled in the art to the normal conditions and operation methods in each method. For details of these general technical means, it is possible to refer to reviews, books and the like. For example, Hiroshi Irie “Radioimmunoassay” (Kodansha, published in 1974), Hiroshi Irie “Continue Radioimmunoassay” (published in Kodansha, 1974), “Enzyme Immunoassay” edited by Eiji Ishikawa et al. 53)), edited by Eiji Ishikawa et al.
- the PPAR ⁇ agonistic activity is prepared by preparing an RNA fraction, a protein fraction or a lipid fraction from a cell, and downstream genes of PPAR ⁇ contained in the fraction (for example, it can be examined by detecting a transcription product, translation product or lipid of apoptosis-related gene, adipocyte differentiation-related gene, arteriosclerosis-related gene, anti-inflammatory-related gene and the like.
- the preparation method of the RNA fraction and the protein fraction and the detection method thereof may be in accordance with the aforementioned method for measuring the PPAR ⁇ expression-inducing activity.
- the lipid may be prepared by a known method.
- a Forch method in which a solvent such as a chloroform-methanol mixture is extracted from a sample containing lipid by adding several times the sample volume
- a Bligh-Dyer method in which a solvent such as a chloroform-methanol-water mixture is added several times and extracted
- a method for detecting the separated lipid it can be detected using a known technique such as liquid chromatography (LC), gas chromatography (GC), high performance liquid chromatography (HPLC) and the like.
- a method for directly detecting lipids contained in fat cells and tissues can also be used. Reagents and the like that can be used in such a method are commercially available.
- HCS LipidTOX phospholipidosis / lipidosis detection kit Invitrogen
- HCS LipidTOX phospholipidosis / lipidosis detection kit can be used.
- a giant cell tumor that develops in bone or soft tissue containing a PPAR ⁇ expression-inducing activity and a PPAR ⁇ agonist activity, preferably a non-steroidal anti-inflammatory agent or a thiazolidine derivative as an active ingredient.
- a PPAR ⁇ expression-inducing activity and a PPAR ⁇ agonist activity preferably a non-steroidal anti-inflammatory agent or a thiazolidine derivative as an active ingredient.
- Those who can be applied for chondrosarcoma prophylactic / therapeutic agents are, for example, those who are clinically diagnosed, suspected of having a giant cell tumor or chondrosarcoma that develops in bone and soft tissue, or future Those who are predicted to develop are included.
- the therapeutic agent of the present invention can be preferably applied to metastatic cancers in which the primary lesion is a giant cell tumor or chondrosarcoma that occurs in the bone / soft part.
- metastatic cancers include lung cancer, colon cancer, breast cancer, prostate cancer, esophageal cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, Examples include pancreatic cancer, brain tumor, blood tumor and the like.
- the preventive or therapeutic agent for giant cell tumor or chondrosarcoma occurring in the bone / soft part of the present invention is orally administered as a tablet, capsule, elixir, microcapsule or the like with sugar coating as necessary. Alternatively, it can be used parenterally in the form of an injectable solution such as a sterile solution with other pharmaceutically acceptable liquid, or a suspension.
- the therapeutic or prophylactic agent should be admixed in a unit dosage form generally required for the practice of the approved formulation with physiologically acceptable carriers, flavoring agents, excipients, vehicles, preservatives, stabilizers, binders, etc. Can be formulated. The amount of the active ingredient in these preparations is appropriately selected in consideration of the dose described later.
- Additives that can be mixed into tablets, capsules and the like include binders such as gelatin, corn starch, tragacanth, gum arabic, excipients such as crystalline cellulose, corn starch, gelatin, alginic acid and the like. Leavening agents, lubricants such as magnesium stearate, sweeteners such as sucrose, lactose or saccharin, flavorings such as peppermint, red oil and cherry.
- a liquid carrier such as fats and oils can be further contained in the above-mentioned type of material.
- Sterile compositions for injection can be formulated according to conventional pharmaceutical practice such as dissolving or suspending active substances in vehicles such as water for injection, naturally occurring vegetable oils such as sesame oil, coconut oil and the like.
- aqueous solutions for injection examples include isotonic solutions (eg, D-sorbitol, D-mannitol, sodium chloride, etc.) containing physiological saline, glucose and other adjuvants, and suitable solubilizing agents.
- an alcohol eg, ethanol
- a polyalcohol eg, propylene glycol, polyethylene glycol, etc.
- a nonionic surfactant eg, polysorbate 80 TM , HCO-50, etc.
- the oily liquid examples include sesame oil and soybean oil, and may be used in combination with benzyl benzoate, benzyl alcohol, or the like as a solubilizing agent.
- buffers eg, phosphate buffer, sodium acetate buffer, etc.
- soothing agents eg, benzalkonium chloride, procaine hydrochloride, etc.
- stabilizers eg, human serum albumin, polyethylene glycol, etc.
- blend with preservatives for example, benzyl alcohol, phenol, etc.
- antioxidant etc.
- the prepared injection solution is usually filled in a suitable ampoule.
- the preparation thus obtained is safe and has low toxicity, it can be used, for example, in mammals (eg, humans, rats, mice, guinea pigs, rabbits, sheep, pigs, cows, horses, cats, dogs, monkeys, etc.). Can be administered.
- mammals eg, humans, rats, mice, guinea pigs, rabbits, sheep, pigs, cows, horses, cats, dogs, monkeys, etc.
- the dosage of the therapeutic or prophylactic agent for giant cell tumor or chondrosarcoma occurring in the bone / soft part of the present invention is the severity of the giant cell tumor or chondrosarcoma occurring in the bone / soft part, administration target, administration route, etc.
- the dose of the therapeutic / prophylactic agent varies depending on the administration subject, severity, etc.
- an amount converted per 60 kg body weight when administered as an injection to an adult (body weight 60 kg), about 0.01 to About 30 mg, preferably about 0.1 to about 20 mg, more preferably about 0.1 to about 10 mg.
- an amount converted per 60 kg body weight can be administered.
- the main method of treatment for giant cell tumor of bone is the removal of the affected area by surgical operation.
- the tumor of the affected area is curetted, and the bone defect is treated with allogeneic bone, autologous bone, or artificial bone.
- Treatment is done by filling.
- this method has a high tumor recurrence rate and entails the risk of metastasis and malignant transformation in the process of repeated recurrence.
- a substance having PPAR ⁇ expression-inducing activity and PPAR ⁇ agonist activity of the present invention preferably a nonsteroidal anti-inflammatory agent or thiazolidine derivative, is contained in an artificial bone used for filling a bone defect portion, thereby Expected to prevent recurrence of giant cell tumor.
- the present invention provides an artificial bone having a PPAR ⁇ expression-inducing activity and having a PPAR ⁇ agonistic activity, preferably a non-steroidal anti-inflammatory agent or a thiazolidine derivative.
- a substance having PPAR ⁇ expression-inducing activity and PPAR ⁇ agonist activity, preferably a nonsteroidal anti-inflammatory agent or thiazolidine derivative, contained in the artificial bone of the present invention can be used as described above.
- the material used for the artificial bone of the present invention include known orthopedic biomaterials such as metal materials, ceramic materials, polymer materials, protein materials, and composite materials thereof.
- the metal material include titanium, titanium alloy, stainless steel, and cobalt-chromium alloy.
- the ceramic material include bio-inert ceramics such as alumina ceramic, single crystal alumina ceramic, and zirconia ceramic, biograss (Hench et al., Biomed. Master.
- Bioactive ceramics such as 2 ).
- the polymer material include polymethyl methacrylate (PMMA), high density polyethylene (HDP), silicon rubber, Teflon, polyester, polylactic acid, PVA hydrogel, and the like.
- the protein material include collagen, fibrin, chitin, chitosan and the like.
- a substance having PPAR ⁇ expression-inducing activity and having a PPAR ⁇ agonistic activity preferably a non-steroidal anti-inflammatory agent or thiazolidine derivative and an artificial bone material mixed or coated with the artificial bone of the present invention
- the content of the substance having expression-inducing activity and PPAR ⁇ agonist activity, preferably a non-steroidal anti-inflammatory agent or thiazolidine derivative is about 1% to about 20%, preferably about 15% to about 20% .
- the present invention also provides a method for screening a prophylactic or therapeutic agent for giant cell tumors or chondrosarcoma that occurs in bone and soft parts.
- the screening method for a prophylactic or therapeutic agent for giant cell tumor or chondrosarcoma occurring in the bone / soft part of the present invention comprises the following steps. (1) a step of culturing a giant cell tumor or chondrosarcoma-derived cell that occurs in a bone / soft part in the presence or absence of a test substance, (2) measuring PPAR ⁇ gene expression and (i) apoptosis-related gene expression, or (ii) adipocyte differentiation-related gene expression or lipid expression under both conditions, (3) PPAR ⁇ gene expression and (i) apoptosis-related gene expression, or (ii) adipocyte differentiation-related gene expression or lipid expression, as compared to the absence of the test substance. A step of selecting a test substance.
- the giant cell tumor or chondrosarcoma-derived cell that occurs in the bone / soft part used in the screening method of the present invention is a giant cell tumor or chondrosarcoma that occurs in the bone / soft part It may be a primary cultured cell derived from the cell or a cell already established. Cell stocks can be prepared according to methods commonly practiced in the art and known literature.
- the giant cell tumor or chondrosarcoma-derived cell that occurs in the bone / soft part may be any tissue (eg, synovium, joint, cartilage, etc.) containing the cell, and the tissue, organ, etc. May be isolated from the living body and cultured, or a test substance may be administered to the living body itself, and these biological samples may be isolated after a certain period of time.
- the cell is cultured in the presence or absence of a test substance.
- the test substance is not particularly limited, and for example, peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts and the like are used. These compounds may be novel compounds or known compounds. Among them, it is preferably expected to be a substance having PPAR ⁇ expression-inducing activity and PPAR ⁇ agonistic activity. Examples of such a test substance include non-steroidal anti-inflammatory agents.
- non-steroidal anti-inflammatory agents examples include zaltoprofen, diclofenac, indomethacin, and the like as described above.
- thiazolidine derivatives may be mentioned as described above. Examples of thiazolidine derivatives include rosiglitazone, pioglitazone, troglitazone, barraglitazone, riboglitazone, and the like.
- the culture may be carried out on an appropriate cell culture substrate.
- an appropriate cell culture substrate for example, flask, tissue culture flask, dish, petri dish, tissue culture dish, multi-dish, micro plate, micro well plate, multi plate, multi well plate , Chamber slide, petri dish, tube, tray, culture bag, and roller bottle.
- the giant cell tumor or chondrosarcoma-derived cell that develops in the bone / soft part may be obtained by suspending the cell suspended as a monocell in a medium and seeding on the cell culture substrate.
- the culture is usually carried out in a 5% CO 2 /95% air, 37 ° C. incubator until confluent.
- a medium suitable for apoptosis of the cell for example, about 5 to 20% fetal bovine serum (FBS)
- FBS fetal bovine serum
- a medium suitable for apoptosis of the cell for example, about 5 to 20% fetal bovine serum (FBS)
- FBS fetal bovine serum
- DMEM Dulbecco's modified Eagle medium
- RPMI 1640 medium 199 medium, F12 medium, etc.
- various buffers eg, HEPES buffer, phosphate buffer, phosphate buffered saline, Tris
- a test substance is added to a hydrochloric acid buffer solution, a borate buffer solution, an acetate buffer solution, etc.) and contacted with cells for a certain period of time.
- the concentration of the test substance to be added varies depending on the type of compound (solubility, toxicity, etc.), but is appropriately selected within the range of, for example, about 1 ⁇ M to about 1000 ⁇ M, preferably about 5 ⁇ M to about 500 ⁇ M, more preferably about 50 ⁇ M to about 200 ⁇ M. Is done.
- Examples of the contact time include about 1 hour to about 48 hours, preferably about 5 hours to 36 hours, more preferably about 10 hours to 24 hours.
- a serum-free medium minimum essential medium (MEM), Dulbecco's modified Eagle medium (DMEM)
- MEM Dulbecco's modified Eagle medium
- RPMI1640 medium 199 medium, F12 medium, etc.
- various buffers eg, HEPES buffer, phosphate buffer, phosphate buffered saline, Tris-HCl buffer, borate buffer, acetate buffer, etc.
- HEPES buffer phosphate buffer, phosphate buffered saline, Tris-HCl buffer, borate buffer, acetate buffer, etc.
- serum for example, about 5 to 20% fetal bovine serum (FBS)
- adipocyte induction aid for example, isobutyl-methylxanthine (IBMX), dexamethasone, insulin, etc.
- IBMX isobutyl-methylxanthine
- other additives include Transferrin, T3, cortisol, asc, calcium pantothenate, biotin and the like.
- a known commercially available adipocyte differentiation kit may be used.
- the concentration of the test substance to be added varies depending on the type of compound (solubility, toxicity, etc.), but is appropriately selected within the range of, for example, about 1 ⁇ M to about 1000 ⁇ M, preferably about 5 ⁇ M to about 500 ⁇ M, more preferably about 50 ⁇ M to about 200 ⁇ M. Is done.
- Examples of the contact time include about 1 hour to about 48 hours, preferably about 5 hours to 36 hours, more preferably about 10 hours to 24 hours.
- the cells may be cultured in a fat differentiation induction medium in parallel with the contact of the test substance, or may be cultured in the fat differentiation induction medium after contacting the test substance for a certain time.
- the screening method of the present invention in the presence or absence of a test substance, together with the expression of the PPAR ⁇ gene, (i) expression of an apoptosis-related gene, or (ii) expression of an adipocyte differentiation-related gene or lipid expression, respectively. taking measurement.
- the expression of the PPAR ⁇ gene can be measured according to the method for measuring the PPAR ⁇ expression-inducing activity described above.
- the expression of apoptosis-related genes, adipocyte differentiation-related genes, and lipids can also be measured according to the aforementioned method for measuring PPAR ⁇ agonist activity.
- PPAR ⁇ expression is not observed in giant cell tumors or chondrosarcoma that develop in bone and soft parts.
- derivation expression of PPAR (gamma) has been confirmed by administration or contact of the non-steroidal anti-inflammatory agent or thiazolidine derivative which has a PPAR (gamma) effect.
- the expression of Caspase3 or lipid was able to be confirmed with the induced expression.
- apoptosis or adipocyte differentiation can be induced in a giant cell tumor or chondrosarcoma that develops in the bone / soft part via PPAR ⁇ , and prevention or treatment of the giant cell tumor or chondrosarcoma that occurs in the bone / soft part.
- Agents can be selected.
- the test substance can be selected as a prophylactic or therapeutic agent for giant cell tumors or chondrosarcoma that develop in bone and soft parts via PPAR ⁇ .
- the amount of PPAR ⁇ gene, apoptosis-related gene, adipocyte differentiation-related gene, lipid expression level is about 20% or more
- a test substance that is preferably increased (or decreased) by about 30% or more, more preferably about 50% or more can be selected as a prophylactic or therapeutic agent for giant cell tumors or chondrosarcoma that develop in bone and soft parts.
- Example 1 Analysis of cell proliferation inhibition and apoptosis after addition of zaltoprofen to giant cell tumor (GCT) cultured cells
- GCT cultured cells (case 1: patient with a giant cell tumor of the distal distal femur, 20s; case 2: right thigh Distal bone giant cell tumor patient, 20s) was cultured in a 96-well culture plate, zaltoprofen was added at each concentration (5, 10, 50, 100, 200 ⁇ M), and after 24 hours, Cell Counting Kit- Color was developed with 8 (CCK-8) (Dojindo), and the absorbance at 450 nm was measured after 3 hours (FIG. 1).
- CCK-8 Cell Counting Kit- Color
- the case1 GCT cultured cells were cultured on a chamber cover slide glass, and after 24 hours, zaltoprofen was added at various concentrations (100, 200 ⁇ M). After 8 hours and 24 hours, the cells were fixed with 4% paraformaldehyde and analyzed for caspase3 staining and Tunel assay for the presence or absence of apoptosis. Observation was performed with a fluorescence microscope (BZ-9000) manufactured by Keyence, and a positive image at each concentration was quantitatively observed (FIG. 2-5). As a result, it was confirmed that the Tunel positive rate and the Caspase 3 positive rate were increased depending on the zaltoprofen concentration and administration time.
- Example 2 PPAR ⁇ immunostaining after addition of zaltoprofen to giant cell tumor (GCT) cultured cells
- GCT giant cell tumor
- the above-mentioned case1 GCT cultured cells were cultured on a chamber cover slide glass, and after 24 hours, zaltoprofen was added at each concentration (10, 50). , 100, 200 ⁇ M). After 24 hours, the cells were fixed with 4% paraformaldehyde and stained with PPAR ⁇ . Observation was performed with a fluorescence microscope (BZ-9000) manufactured by Keyence, and positive images at each concentration were quantitatively observed (FIGS. 6 and 7). As a result, the expression of PPAR ⁇ was about 15% in Control, but it was confirmed that the expression of PPAR ⁇ was increased depending on the zaltoprofen concentration.
- Example 3 Analysis of Adipocyte Differentiation of GCT Cultured Cells After Addition of Zaltoprofen to Giant Cell Tumor (GCT) Cultured Cells PPAR ⁇ has been reported to be an essential transcription factor for adipocyte differentiation. Therefore, the above-mentioned case1 GCT cultured cells were cultured on a chamber cover slide glass, and when they became confluent, zaltoprofen was added at each concentration (10, 50, 100 ⁇ M). After 24 hours, the cells were cultured for 7 to 14 days in a fat differentiation induction medium (STREPRO Adipogenesis Differentiation Kit; Invitrogen), and differentiation into adipocytes was analyzed with HCS LipidTOX Green neutral lipid stain (Invitrogen) (FIGS. 8 and 9). As a result, although the positive image of HCS LipidTOX Green was slight in Control, it was confirmed that the positive image of HCS LipidTOX Green was enhanced depending on the zaltoprofen concentration.
- Example 4 Analysis of apoptosis of cells derived from giant cell tumor (GCT) patient administered with zaltoprofen Three tablets of Soleton Tablets 80 (generic name: zaltoprofen 80 mg, Nippon Chemifa Co., Ltd.), which is a zaltoprofen tablet, for pain due to tumor
- Soleton Tablets 80 (generic name: zaltoprofen 80 mg, Nippon Chemifa Co., Ltd.), which is a zaltoprofen tablet, for pain due to tumor
- the surgical resection specimen of a man in his thirties who had undergone surgery after being administered for about 28 days per day, and the surgical resection specimen of a giant cell tumor of osteosarcoma not treated with zaltoprofen were stained with Caspase3 and subjected to Tunel assay for apoptosis. The presence or absence was analyzed.
- Example 5 PPAR ⁇ immunostaining of cells derived from giant cell tumor (GCT) patients administered with zaltoprofen Three tablets of Soleton Tablets 80 (generic name: zaltoprofen 80 mg, Nippon Chemifa Co., Ltd.), which is a zaltoprofen tablet, for pain caused by tumor Analyzing the expression of PPAR ⁇ by staining surgically resected specimens of males in their 30s who were administered for about 28 days per day and surgically resected specimens of bone giant cell tumors not treated with zaltoprofen did. Observation was performed with a fluorescence microscope (BZ-9000) manufactured by Keyence (FIG. 11).
- Example 6 Analysis of cell growth inhibition after addition of non-steroidal anti-inflammatory agent to giant cell tumor (GCT) cultured cells
- GCT cultured cells (case 1, case 2) were cultured in the same manner as in Example 1, and non-steroids were cultured. Absorbance at 450 nm was measured by adding various anti-inflammatory agents (acetaminophen, indomethacin or diclofenac) or troglitazone at each concentration (FIGS. 12 and 13). As a result, it was confirmed that cell proliferation was suppressed in a non-steroidal anti-inflammatory drug concentration-dependent manner.
- various anti-inflammatory agents acetaminophen, indomethacin or diclofenac
- troglitazone at each concentration
- Example 7 Effect of PPAR ⁇ siRNA on giant cell tumor (GCT) cultured cells after addition of nonsteroidal anti-inflammatory agent
- Cells (case 1, case 2) were cultured in 96-well culture plates, and PPAR ⁇ siRNA, negative control siRNA and transfection reagent (Thermo Scientific Dharma FECT: Thermo Scientific) was reacted for 48 hours and then cultured in a normal culture solution for 48 hours, after which zaltoprofen was added at 200 ⁇ M or troglitazone at 60 ⁇ M, and after 72 hours Cell Counting KIT-8 (Cell Counting Kit-8) -8) Color was developed by (Dojindo), and the absorbance at 450 nm was measured after 3 hours (FIGS. 14 and 15). As a result, it was confirmed that the effect of zaltoprofen was significantly suppressed in the PPAR ⁇ siRNA added group.
- Example 8 Cell Growth Inhibition and Apoptosis after Addition of Nonsteroidal Anti-Inflammatory Agent or Thiazolidine Derivative to GCT of Tendon Sheath-Derived Cells or Pigmented-type GCT Syndritis-Derived Cells Analysis of tendon sheath giant cell tumor cultured cell (right knee tendon sheath giant cell tumor patient, 30s) and pigmented chorio-nodular synovitis cultured cell (left knee pigmented chorio-nodal synovitis) Patient, 30s) was cultured, and zaltoprofen or troglitazone was added at each concentration, and the absorbance was measured (FIGS. 16 and 17).
- Example 9 PPAR ⁇ immunostaining after addition of non-steroidal anti-inflammatory agent or thiazolidine derivative to cells derived from GCT of tendon sheath or diffuse-type GCT-derived cells Similar to 2, Zaltoprofen was added at a concentration of 400 ⁇ M or troglitazone at a concentration of 200 ⁇ M to giant cell tumor cells derived from tendon sheath giant cell tumor or cells derived from pigmented chorionodular synovitis, and PPAR ⁇ positive images were observed (FIGS. 26-29). As a result, expression of PPAR ⁇ was confirmed in the zaltoprofen or troglitazone-added cells.
- Example 10 Analysis of Adipocyte Differentiation of GCT of Tendon Sheath-Derived Cells or Pigmented-type GCT Syndritis-Derived Cells After Addition of Nonsteroidal Anti-inflammatory Agents
- Example 3 PPAR ⁇ has been reported to be an essential transcription factor for adipocyte differentiation. Therefore, zaltoprofen was added at a concentration of 400 ⁇ M to cells derived from giant cell tumor of tendon sheath or cells derived from pigmented chorionic nodular synovitis, and differentiation into adipocytes was analyzed (FIGS. 30 and 31). As a result, it was confirmed that the positive image of HCS LipidTOX Green was enhanced in the zaltoprofen-added cells as compared with Control.
- Example 11 Analysis of cell growth inhibition after addition of pioglitazone to giant cell tumor (GCT) cultured cells
- GCT giant cell tumor
- cultured GCT cells case 1, case 2
- giant cell tumor of tendon sheath GCT of tendon sheet
- the cells derived from the cells or cells derived from diffuse-type GCT were cultured, and thiazolidine derivative pioglitazone was added at each concentration, and the absorbance at 450 nm was measured (FIG. 32). As a result, it was confirmed that cell proliferation was suppressed depending on the pioglitazone concentration.
- Example 12 Analysis of MRI image of giant cell tumor (GCT) patient, giant cell tumor of tendon sheath or patient with pigmented chorionodular synovitis administered zaltoprofen Osteocytoma patient, giant cell tumor of tendon sheath or pigmented Soleton Tablets 80 (generic name: zaltoprofen 80 mg, Nippon Chemifa Co., Ltd.) 3 tablets / day (1 tablet each in the morning, noon, and evening) for patients with chorionodular synovitis, several months Each time the size of the tumor was assessed by MRI.
- GCT giant cell tumor
- Example 13 Analysis of cell growth inhibition and apoptosis after addition of non-steroidal anti-inflammatory agent or thiazolidine derivative to chondrosarcoma-derived cell line (H-EMC-SS)
- H-EMC-SS chondrosarcoma-derived cell line
- Example 1 the chondrosarcoma-derived cell line was stained with Caspase3 to analyze the presence or absence of apoptosis (FIGS. 46 and 47). As a result, it was confirmed that the Caspase3 positive rate was increased in cells to which zaltoprofen was added at a concentration of 200 ⁇ M and troglitazone was added at a concentration of 100 ⁇ M or pioglitazone was added at a concentration of 200 ⁇ M, compared to Control.
- Example 14 PPAR ⁇ immunostaining after addition of non-steroidal anti-inflammatory agent or thiazolidine derivative to chondrosarcoma-derived cell line (H-EMC-SS)
- H-EMC-SS chondrosarcoma-derived cell line
- zaltoprofen was added to chondrosarcoma-derived cell line at a concentration of 200 ⁇ M
- Troglitazone was added at a concentration of 100 ⁇ M or pioglitazone was added at a concentration of 200 ⁇ M
- PPAR ⁇ positive images were observed (FIGS. 48 and 49).
- expression of PPAR ⁇ could be confirmed in zaltoprofen, troglitazone or pioglitazone-added cells.
- the prophylactic or therapeutic agent of the present invention is effective for patients with giant cell tumors or chondrosarcoma that develop in bones / soft parts or those who may develop giant cell tumors or chondrosarcomas that occur in bones / soft parts. . Further, according to the present invention, by selecting a PPAR ⁇ gene and a test substance that controls apoptosis or adipocyte differentiation, it is possible to search for a novel therapeutic agent for giant cell tumor or chondrosarcoma that occurs in bone and soft parts. Become. This application is based on Japanese Patent Application No. 2012-070351 (filing date: March 26, 2012) and Japanese Patent Application No. 2012-235784 (filing date: October 25, 2012) filed in Japan. All contents are intended to be included herein.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
Abstract
Description
骨巨細胞腫は、若年~中高年の膝関節周囲に好発する良性腫瘍で、男女比は1:1.3~1.5で女性の罹患率が高い。また、全骨腫瘍のうちの約5%、良性骨腫瘍のうちの約20%を占めており、良性腫瘍ではあるが、再発率が10~30%と高く、また時に肺転移や悪性転化により治療に難渋する場合がある。病理所見では多核巨細胞と単球細胞の増生が主体で、間に紡錘型細胞をみとめる。腫瘍の本体は、この多核巨細胞ではなく、間質に存在する線維芽細胞様の紡錘形細胞と考えられている。さらに膝関節、肩関節、手関節などの関節近傍に発生するため、いかに再発を予防しかつ関節機能を温存する治療を行うかが重要である。
腱鞘巨細胞腫は、腱鞘、関節、滑液包の滑膜から発生する腫瘍性疾患である。病変の増殖型に基づいて限局型とびまん型に分類され、一般的に限局型の病変は腱鞘巨細胞腫、びまん型の腱鞘巨細胞腫は色素性絨毛結節性滑膜炎と同義とされている。腱鞘巨細胞腫は、30~50歳代の女性に好発し、手指の関節近傍や屈筋腱上に約85%が発生し、次いで足趾に発生する。骨内に浸潤することもある。病理所見では、卵円形~紡錘形の組織球様単核細胞が主体で、多核巨細胞と泡沫細胞にヘモジデリン沈着を伴う。治療は、良性腫瘍に準じて腫瘍切除術(単純摘出術)を行うが、再発率は4~30%と報告されている。
色素性絨毛結節性滑膜炎は、40歳以下の比較的若年成人でやや女性に多く、膝関節が最も多く、股・足・肘・肩関節などにも発生する。関節内に滑膜の絨毛像や結節様の増殖をきたし、関節血症をしばしば認め、また骨内にも浸潤するため二次変形性関節症を生じる。病理所見では、滑膜細胞様の単核細胞と多核巨細胞、泡沫細胞、ヘモジデリン貪食細胞、炎症性細胞などが混在する。治療は、手術で腫瘍を切除するが全切除が困難で、再発率は40~50%と高い。
骨巨細胞腫、腱鞘巨細胞腫、色素性絨毛結節性滑膜炎はいずれも、現時点では手術以外の有効な治療法は開発されていない。
軟骨肉腫は原発性悪性骨腫瘍の約20%を占め、骨肉腫に次いで頻度が高い。組織学的に通常型軟骨肉腫、骨膜性軟骨肉腫、間葉性軟骨肉腫、脱分化型軟骨肉腫、淡明細胞型軟骨肉腫、骨外性粘液型軟骨肉腫などに分類される。通常型は、30~50歳代に好発しやや男性に多い。骨盤骨に最も多く発生し、次いで肋骨・大腿骨近位・上腕骨近位・大腿骨遠位に多い。間葉性軟骨肉腫は通常型軟骨肉腫よりも若い10~30歳代に好発し、顎骨・脊椎・腸骨・肋骨・大腿骨遠位部などに好発する。脱分化型軟骨肉腫は、低悪性通常型軟骨肉腫から非軟骨性高悪性腫瘍が生じるもので、両者は明瞭な境界をもって隣接している。50~60歳代に好発し、大腿骨が最も多く、次いで骨盤・上腕骨に多い。淡明細胞型軟骨肉腫は、20~50歳代に好発し、約2/3は上腕骨骨頭・大腿骨骨頭に発生する。その他、頭蓋骨・脊椎・手足の骨に発生する。骨外性粘液型軟骨肉腫は、40~50歳代に好発し、大腿などの四肢の近位部や体幹の深部軟部組織や四肢末端部や縦隔、後腹膜などの軟部組織に生じることがある。これらは、現在のところ手術以外の有効な治療は開発されていない。
本発明者らは、これらの知見に基づいてさらに研究を重ねた結果、本発明を完成するに至った。
[1]非ステロイド性抗炎症剤またはチアゾリジン誘導体を有効成分として含有する、骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤;
[2]非ステロイド性抗炎症剤がザルトプロフェン、ジクロフェナク、インドメタシン、オキサプロジン、アセトアミノフェンおよびケトプロフェンからなる群から選択される、前記[1]に記載の予防または治療剤;
[3]チアゾリジン誘導体がトログリタゾン、ロシグリタゾン、ピオグリタゾン、バラグリタゾンおよびリボグリタゾンからなる群から選択される、前記[1]に記載の予防または治療剤;
[4]骨・軟部に発生する巨細胞性腫瘍が、骨巨細胞腫、腱鞘巨細胞腫および色素性絨毛結節性滑膜炎からなる群から選択される、前記[1]から[3]のいずれか1つに記載の予防または治療剤;
[5]以下の工程を含む、骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤のスクリーニング方法
(1)骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫由来細胞を被検物質の存在下または非存在下で培養する工程、
(2)両条件下、PPARγ遺伝子の発現、および
(i)アポトーシス関連遺伝子の発現、または
(ii)脂肪細胞分化関連遺伝子の発現もしくは脂質の発現
をそれぞれ測定する工程、
(3)被検物質非存在下と比較して、PPARγ遺伝子の発現、および
(i)アポトーシス関連遺伝子の発現、または
(ii)脂肪細胞分化関連遺伝子の発現もしくは脂質の発現
を有意に変動させる被検物質を選択する工程;
[6]骨・軟部に発生する巨細胞性腫瘍が、骨巨細胞腫、腱鞘巨細胞腫および色素性絨毛結節性滑膜炎からなる群から選択される、前記[5]に記載のスクリーニング方法;
[7]非ステロイド性抗炎症剤またはチアゾリジン誘導体の有効量を対象に投与することを含む、骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療方法;
[8]非ステロイド性抗炎症剤がザルトプロフェン、ジクロフェナク、インドメタシン、オキサプロジン、アセトアミノフェンおよびケトプロフェンからなる群から選択される、前記[7]に記載の予防または治療方法;
[9]チアゾリジン誘導体がトログリタゾン、ロシグリタゾン、ピオグリタゾン、バラグリタゾンおよびリボグリタゾンからなる群から選択される、前記[7]に記載の予防または治療方法;
[10]骨・軟部に発生する巨細胞性腫瘍が、骨巨細胞腫、腱鞘巨細胞腫および色素性絨毛結節性滑膜炎からなる群から選択される、前記[7]から[9]のいずれか1つに記載の予防または治療方法;
[11]骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療に使用するための、非ステロイド性抗炎症剤またはチアゾリジン誘導体;
[12]非ステロイド性抗炎症剤がザルトプロフェン、ジクロフェナク、インドメタシン、オキサプロジン、アセトアミノフェンおよびケトプロフェンからなる群から選択される、前記[11]に記載の非ステロイド性抗炎症剤またはチアゾリジン誘導体;
[13]チアゾリジン誘導体がトログリタゾン、ロシグリタゾン、ピオグリタゾン、バラグリタゾンおよびリボグリタゾンからなる群から選択される、前記[11]に記載の非ステロイド性抗炎症剤またはチアゾリジン誘導体;
[14]骨・軟部に発生する巨細胞性腫瘍が、骨巨細胞腫、腱鞘巨細胞腫および色素性絨毛結節性滑膜炎からなる群から選択される、前記[11]から[13]のいずれか1つに記載の非ステロイド性抗炎症剤またはチアゾリジン誘導体;
などを提供する。
また、本発明の予防または治療剤が適用できる軟骨肉腫としては、通常型軟骨肉腫、骨膜性軟骨肉腫、間葉性軟骨肉腫、脱分化型軟骨肉腫、淡明細胞型軟骨肉腫、骨外性粘液型軟骨肉腫などが挙げられる。
あるいは、本発明の予防または治療剤は、PPARγの発現を認める腫瘍に用いることもできる。PPARγの発現を認める腫瘍としては、乳癌、大腸癌、肺癌、甲状腺癌、食道癌、胃癌、膵臓癌、肝臓癌、腎臓癌、膀胱癌、卵巣癌、子宮頸癌、前立腺癌、悪性黒色腫、白血病、悪性リンパ腫、脂肪肉腫、平滑筋肉腫、骨肉腫などが挙げられる。
PCRにおいてプライマーとして用いられるオリゴヌクレオチドのセットとしては、例えば、前述のPPARγ遺伝子の転写産物を特異的に検出し得る核酸プライマーを挙げることができる。1つの好ましい態様においては、本発明の検査方法に用いられる核酸プライマーとしては、約15塩基以上、好ましくは約15~約50塩基、より好ましくは約15~約30塩基、いっそう好ましくは約15~約25塩基の連続したヌクレオチド配列の長さを有し、約100bp~数kbpのDNA断片を増幅するようにデザインされたポリヌクレオチド(センス鎖)配列に相補的なポリヌクレオチド、及び前記のポリヌクレオチド配列に相補的なヌクレオチド配列を有するポリヌクレオチド(アンチセンス鎖)にハイブリダイズし得るポリヌクレオチドのオリゴヌクレオチドのセットが挙げられる。
本発明の人工骨に用いる材料としては、公知の整形外科用生体材料、例えば、金属材料、セラミックス材料、高分子材料、タンパク質材料またはこれらの複合材料が挙げられる。
上記金属材料としては、例えば、チタン、チタン合金、ステンレス、コバルト-クロム合金等が挙げられる。
上記セラミックス材料としては、例えば、アルミナセラミック、単結晶アルミナセラミック、ジルコニアセラミック等のバイオイナート・セラミックス、バイオグラス(Hench等、Biomed.Master.Symp.,2,117(1972))、ヒドロキシアパタイト(青木ら、セラミックス,10,469(1975))、アパタイト-ウオラストナイト(AW)-ガラス(Bull.Inst.Chem.Res.KyotoUni.,60,260(1982))、TCPセラミックス(Ca3(PO4)2)等のバイオアクティブ・セラミックスが挙げられる。
上記高分子材料としては、例えば、ポリメチルメタクリレート(PMMA)、高密度ポリエチレン(HDP)、シリコンラバー、テフロン、ポリエステル、ポリ乳酸、PVAハイドロゲル等が挙げられる。
上記タンパク質材料としては、例えば、コラーゲン、フィブリン、キチン、キトサン等が挙げられる。
(1)骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫由来細胞を被検物質の存在下または非存在下で培養する工程、
(2)両条件下、PPARγ遺伝子の発現、および
(i)アポトーシス関連遺伝子の発現、または
(ii)脂肪細胞分化関連遺伝子の発現もしくは脂質の発現
をそれぞれ測定する工程、
(3)被検物質非存在下と比較して、PPARγ遺伝子の発現、および
(i)アポトーシス関連遺伝子の発現、または
(ii)脂肪細胞分化関連遺伝子の発現もしくは脂質の発現を有意に変動させる被検物質を選択する工程。
本発明において、被検物質は、特に制限があるわけではなく、例えば、ペプチド、タンパク質、非ペプチド性化合物、合成化合物、発酵生産物、細胞抽出液、植物抽出液、動物組織抽出液などが用いられ、これら化合物は新規な化合物であってもよいし、公知の化合物であってもよい。そのなかでも、PPARγの発現誘導活性を有し、かつPPARγの作動活性を有する物質であることが好ましく期待される。そのような被検物質としては、非ステロイド性抗炎症剤が挙げられる。非ステロイド性抗炎症剤としては、上記と同様に、ザルトプロフェン、ジクロフェナク、インドメタシンなどが挙げられる。また、非ステロイド性抗炎症剤以外では、例えば、上記と同様にチアゾリジン誘導体が挙げられる。チアゾリジン誘導体としては、例えば、ロシグリタゾン、ピオグリタゾン、トログリタゾン、バラグリタゾン、リボグリタゾンなどが挙げられる。
GCT培養細胞(case1:右大腿骨遠位部骨巨細胞腫患者、20歳代;case2:右大腿骨遠位部骨巨細胞腫患者、20歳代)を、96wellの培養プレートで培養し、ザルトプロフェンを各濃度(5、10、50、100、200μM)で添加し、24時間後にCell Counting Kit-8(CCK-8)(Dojindo社)で発色し、3時間後に450nmの吸光度を測定した(図1)。その結果、ザルトプロフェン濃度依存的に、細胞増殖が抑制されていることが確認できた。
また、上記case1のGCT培養細胞を、チャンバーカバースライドガラス上に培養し、24時間後にザルトプロフェンを、各濃度(100、200μM)で添加した。8時間後と24時間後に、4%パラホルムアルデヒドで固定し、Caspase3の染色と、Tunel assayを行いアポトーシスの有無について解析した。観察は、Keyence社の蛍光顕微鏡(BZ-9000)で行い、各濃度における陽性像を定量的に観察した(図2-5)。その結果、ザルトプロフェン濃度および投与時間依存的に、Tunel陽性率およびCaspase3陽性率が上昇されていることが確認できた。
上記case1のGCT培養細胞を、チャンバーカバースライドガラス上に培養し、24時間後に、ザルトプロフェンを、各濃度(10、50、100、200μM)で添加した。24時間後に、4%パラホルムアルデヒドで固定し、PPARγの染色を行った。観察は、Keyence社の蛍光顕微鏡(BZ-9000)で行い、各濃度における陽性像を定量的に観察した(図6、7)。その結果、ControlではPPARγの発現は約15%であったが、ザルトプロフェン濃度依存的に、PPARγの発現が亢進していることが確認できた。
PPARγは、脂肪細胞分化に必須の転写因子であることが報告されている。そこで、上記case1のGCT培養細胞を、チャンバーカバースライドガラス上に培養し、コンフレントとなったところで、ザルトプロフェンを、各濃度(10、50、100μM)で添加した。24時間後より脂肪分化誘導培地(STREMPRO Adipogenesis Differentiation Kit;Invitrogen)で7~14日培養し、脂肪細胞への分化をHCS LipidTOX Green neutral lipid stain(Invitrogen)で解析した(図8、9)。その結果、ControlではHCS LipidTOX Greenの陽性像がわずかであったが、ザルトプロフェン濃度依存的に、HCS LipidTOX Greenの陽性像が亢進していることが確認できた。
腫瘍による疼痛に対して、ザルトプロフェン錠であるソレトン錠80(一般名:ザルトプロフェン80mg、日本ケミファ株式会社)を3錠/日で約28日間投与された後に手術を施行した30代の男性の手術切除標本と、対象としてザルトプロフェン未投与の骨巨細胞腫の手術切除標本をCaspase3の染色と、Tunel assayを行いアポトーシスの有無について解析した。観察は、Keyence社の蛍光顕微鏡(BZ-9000)で行った(図10)。その結果、ザルトプロフェン未投与のGCT患者由来の細胞ではTunel陽性細胞およびCaspase3陽性細胞がほとんど確認できなかったが、ザルトプロフェン投与された患者由来の細胞では、Tunel陽性細胞およびCaspase3陽性細胞が確認できた。
腫瘍による疼痛に対して、ザルトプロフェン錠であるソレトン錠80(一般名:ザルトプロフェン80mg、日本ケミファ株式会社)を3錠/日で約28日間投与された後に手術を施行した30代の男性の手術切除標本と、対象としてザルトプロフェン未投与の骨巨細胞腫の手術切除標本をPPARγの染色を行い、PPARγの発現を解析した。観察は、Keyence社の蛍光顕微鏡(BZ-9000)で行った(図11)。その結果、ザルトプロフェン未投与のGCT患者由来の細胞ではPPARγ発現細胞がほとんど確認できなかったが、ザルトプロフェン投与された患者由来の細胞では、PPARγ発現細胞が確認でき、さらに脂肪分化が確認された。
実施例1と同様の方法で、GCT培養細胞(case1、case2)を培養し、非ステロイド性抗炎症剤(アセトアミノフェン、インドメタシンまたはジクロフェナク)またはトログリタゾンを各濃度で添加して450nmの吸光度を測定した(図12、13)。その結果、非ステロイド性抗炎症剤濃度依存的に、細胞増殖が抑制されていることが確認できた。
96wellの培養プレートで細胞(case1、case2)を培養し、PPARγsiRNA、ネガティブコントロールsiRNAおよびトランスフェクション試薬のみ(Thermo Scientific DharmaFECT:Thermo Scientific社)を48時間反応させたのちに通常の培養液で48時間培養し、その後ザルトプロフェンを200μMまたはトログリタゾンを60μMで添加し、72時間後にCell Counting Kit-8(CCK-8)(Dojindo社)で発色し、3時間後に450nmの吸光度を測定した(図14、15)。その結果、PPARγ siRNA添加群では、ザルトプロフェンの効果が有意に抑制されたことが確認できた。
実施例1と同様に、腱鞘巨細胞腫培養細胞(右膝腱鞘巨細胞腫患者、30歳代)および色素性絨毛結節性滑膜炎培養細胞(左膝色素性絨毛結節性滑膜炎患者、30歳代)を培養し、ザルトプロフェンまたはトログリタゾンを各濃度で添加し、吸光度を測定した(図16、17)。その結果、ザルトプロフェンまたはトログリタゾン濃度依存的に、細胞増殖が抑制されていることが確認できた。
また実施例1と同様に、腱鞘巨細胞腫培養細胞および色素性絨毛結節性滑膜炎培養細胞について、Caspase3の染色およびTunel assayを行いアポトーシスの有無を解析した(図18-25)。その結果、ザルトプロフェンを濃度400μMまたはトログリタゾンを濃度200μMで添加された細胞は、Controlに比べて、Tunel陽性率およびCaspase3陽性率が上昇していることが確認できた。
実施例2と同様に、腱鞘巨細胞腫由来細胞または色素性絨毛結節性滑膜炎由来細胞に、ザルトプロフェンを濃度400μMまたはトログリタゾンを濃度200μMで添加し、PPARγ陽性像を観察した(図26-29)。その結果、ザルトプロフェンまたはトログリタゾン添加細胞ではPPARγの発現が確認できた。
実施例3と同様に、PPARγは、脂肪細胞分化に必須の転写因子であることが報告されている。そこで、腱鞘巨細胞腫由来細胞または色素性絨毛結節性滑膜炎由来細胞に、ザルトプロフェンを濃度400μMで添加し、脂肪細胞への分化を解析した(図30、31)。その結果、ザルトプロフェン添加細胞ではHCS LipidTOX Greenの陽性像がControlに比べて亢進していることが確認できた。
実施例1と同様の方法で、GCT培養細胞(case1、case2)、腱鞘巨細胞腫(GCT of tendon sheath)由来細胞または色素性絨毛結節性滑膜炎(diffuse-type GCT)由来細胞を培養し、チアゾリジン誘導体であるピオグリタゾンを各濃度で添加して450nmの吸光度を測定した(図32)。その結果、ピオグリタゾン濃度依存的に、細胞増殖が抑制されていることが確認できた。
骨巨細胞腫患者、腱鞘巨細胞腫患者または色素性絨毛結節性滑膜炎患者に対して、ソレトン錠80(一般名:ザルトプロフェン80mg、日本ケミファ株式会社)を3錠/日(朝・昼・夕に1錠ずつ服用)で服用させ、数か月ごとにMRIで腫瘍のサイズを評価した。代表症例として、骨巨細胞腫の骨盤部再発例(34歳、女性:図33、34)において、2ヶ月後(図35)、4ヵ月後(図36)において次第に腫瘍の縮退が確認できた。また、右膝の色素性絨毛結節性滑膜炎の再発例(26歳、女性:図37、38)において、3ヵ月後(図39、40)にMRI造影効果の減弱が確認でき、疼痛・膝関節可動域に改善が見られた。さらに、別の右膝の色素性絨毛結節性滑膜炎の再発例(38歳、女性:図41、42)において2ヵ月後(図43、44)に腫瘤の縮小が確認でき、疼痛改善が見られた。
実施例1と同様に、軟骨肉腫由来細胞株を培養し、トログリタゾン、ピオグリタゾンまたはザルトプロフェンを各濃度で添加し、吸光度を測定した(図45)。その結果、トログリタゾン、ピオグリタゾンまたはザルトプロフェン濃度依存的に、細胞増殖が抑制されていることが確認できた。
また実施例1と同様に、軟骨肉腫由来細胞株について、Caspase3の染色を行いアポトーシスの有無を解析した(図46、47)。その結果、ザルトプロフェンを濃度200μM、トログリタゾンを濃度100μMまたはピオグリタゾンを濃度200μMで添加された細胞は、Controlに比べて、Caspase3陽性率が上昇していることが確認できた。
実施例2と同様に、軟骨肉腫由来細胞株に、ザルトプロフェンを濃度200μM、トログリタゾンを濃度100μMまたはピオグリタゾンを濃度200μMで添加し、PPARγ陽性像を観察した(図48、49)。その結果、ザルトプロフェン、トログリタゾンまたはピオグリタゾン添加細胞ではPPARγの発現が確認できた。
本出願は、日本で出願された特願2012-070351(出願日:平成24年3月26日)および特願2012-235784(出願日:平成24年10月25日)を基礎としており、その内容はすべて本明細書に包含されるものとする。
Claims (14)
- 非ステロイド性抗炎症剤またはチアゾリジン誘導体を有効成分として含有する、骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤。
- 非ステロイド性抗炎症剤がザルトプロフェン、ジクロフェナク、インドメタシン、オキサプロジン、アセトアミノフェンおよびケトプロフェンからなる群から選択される、請求項1に記載の予防または治療剤。
- チアゾリジン誘導体がトログリタゾン、ロシグリタゾン、ピオグリタゾン、バラグリタゾンおよびリボグリタゾンからなる群から選択される、請求項1に記載の予防または治療剤。
- 骨・軟部に発生する巨細胞性腫瘍が、骨巨細胞腫、腱鞘巨細胞腫および色素性絨毛結節性滑膜炎からなる群から選択される、請求項1から3のいずれか1項に記載の予防または治療剤。
- 以下の工程を含む、骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤のスクリーニング方法
(1)骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫由来細胞を被検物質の存在下または非存在下で培養する工程、
(2)両条件下、PPARγ遺伝子の発現、および
(i)アポトーシス関連遺伝子、または
(ii)脂肪細胞分化関連遺伝子の発現もしくは脂質の発現
をそれぞれ測定する工程、
(3)被検物質非存在下と比較して、PPARγ遺伝子の発現、および
(i)アポトーシス関連遺伝子、または
(ii)脂肪細胞分化関連遺伝子の発現もしくは脂質の発現
を有意に変動させる被検物質を選択する工程。 - 骨・軟部に発生する巨細胞性腫瘍が、骨巨細胞腫、腱鞘巨細胞腫および色素性絨毛結節性滑膜炎からなる群から選択される、請求項5に記載のスクリーニング方法。
- 非ステロイド性抗炎症剤またはチアゾリジン誘導体の有効量を対象に投与することを含む、骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療方法。
- 非ステロイド性抗炎症剤がザルトプロフェン、ジクロフェナク、インドメタシン、オキサプロジン、アセトアミノフェンおよびケトプロフェンからなる群から選択される、請求項7に記載の予防または治療方法。
- チアゾリジン誘導体がトログリタゾン、ロシグリタゾン、ピオグリタゾン、バラグリタゾンおよびリボグリタゾンからなる群から選択される、請求項7に記載の予防または治療方法。
- 骨・軟部に発生する巨細胞性腫瘍が、骨巨細胞腫、腱鞘巨細胞腫および色素性絨毛結節性滑膜炎からなる群から選択される、請求項7から9のいずれか1項に記載の予防または治療方法。
- 骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療に使用するための、非ステロイド性抗炎症剤またはチアゾリジン誘導体。
- 非ステロイド性抗炎症剤がザルトプロフェン、ジクロフェナク、インドメタシン、オキサプロジン、アセトアミノフェンおよびケトプロフェンからなる群から選択される、請求項11に記載の非ステロイド性抗炎症剤またはチアゾリジン誘導体。
- チアゾリジン誘導体がトログリタゾン、ロシグリタゾン、ピオグリタゾン、バラグリタゾンおよびリボグリタゾンからなる群から選択される、請求項11に記載の非ステロイド性抗炎症剤またはチアゾリジン誘導体。
- 骨・軟部に発生する巨細胞性腫瘍が、骨巨細胞腫、腱鞘巨細胞腫および色素性絨毛結節性滑膜炎からなる群から選択される、請求項11から13のいずれか1項に記載の非ステロイド性抗炎症剤またはチアゾリジン誘導体。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380016296.XA CN104302322A (zh) | 2012-03-26 | 2013-03-18 | 骨·软组织中产生的巨细胞性肿瘤或软骨肉瘤的预防或治疗剂 |
KR1020147029881A KR102199273B1 (ko) | 2012-03-26 | 2013-03-18 | 뼈 및 연부에 발생하는 거대 세포성 종양 또는 연골 육종의 예방 및 치료제 |
JP2014507736A JP5865995B2 (ja) | 2012-03-26 | 2013-03-18 | 骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤 |
EP13769796.7A EP2832367B1 (en) | 2012-03-26 | 2013-03-18 | Agent for preventing or treating giant cell tumor or chondrosarcoma arising in bone/soft tissue |
US14/387,981 US10660882B2 (en) | 2012-03-26 | 2013-03-18 | Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma |
SG11201406032TA SG11201406032TA (en) | 2012-03-26 | 2013-03-18 | Prophylactic or therapeutic agent for giant cell tumors occuring in bone and soft tissue or for chondrosarcoma |
NZ700872A NZ700872A (en) | 2012-03-26 | 2013-03-18 | Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma |
AU2013238126A AU2013238126C1 (en) | 2012-03-26 | 2013-03-18 | Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma |
CA2868311A CA2868311C (en) | 2012-03-26 | 2013-03-18 | Use of non-steroidal anti-inflammatory drugs (nsaids) and thiazolidinediones in the treatment of giant cell tumors occurring in a bone or soft tissue or of chondrosarcoma |
HK15104298.4A HK1203818A1 (en) | 2012-03-26 | 2015-05-06 | Agent for preventing or treating giant cell tumor or chondrosarcoma arising in bone soft tissue |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012070351 | 2012-03-26 | ||
JP2012-070351 | 2012-03-26 | ||
JP2012235784 | 2012-10-25 | ||
JP2012-235784 | 2012-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013146435A1 true WO2013146435A1 (ja) | 2013-10-03 |
Family
ID=49259696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/057706 WO2013146435A1 (ja) | 2012-03-26 | 2013-03-18 | 骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10660882B2 (ja) |
EP (1) | EP2832367B1 (ja) |
JP (2) | JP5865995B2 (ja) |
KR (1) | KR102199273B1 (ja) |
CN (2) | CN104302322A (ja) |
AU (1) | AU2013238126C1 (ja) |
CA (1) | CA2868311C (ja) |
HK (1) | HK1203818A1 (ja) |
NZ (1) | NZ700872A (ja) |
SG (1) | SG11201406032TA (ja) |
WO (1) | WO2013146435A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016540044A (ja) * | 2013-11-18 | 2016-12-22 | 中国医学科学院生物医学工程研究所Institute Of Biomedical Engineering, Chinese Academy Of Medical Science | 新規な抗hpv医薬製剤の用途 |
JP2018501254A (ja) * | 2014-12-22 | 2018-01-18 | ファイヴ プライム セラピューティクス インク | Pvnsを治療するための抗csf1r抗体 |
JP2018536011A (ja) * | 2015-12-01 | 2018-12-06 | テリアカ バイオメディカル インコーポレイテッドTheriac Biomedicale Inc. | PPARγ活性化剤とその使用 |
US10653667B2 (en) | 2013-09-25 | 2020-05-19 | Nippon Chemiphar Co., Ltd | Drug for preventing, treating or preventing metastasis of giant cell tumor that occurs in bone or soft parts, chondrosarcoma, or osteosarcoma, local injection for arterial embolization, and artificial bone |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013146435A1 (ja) | 2012-03-26 | 2013-10-03 | 日本ケミファ株式会社 | 骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤 |
JP6703824B2 (ja) * | 2015-11-30 | 2020-06-03 | シスメックス株式会社 | 細胞選択方法、細胞検出方法、細胞選択装置、および細胞検出装置 |
KR102650228B1 (ko) | 2021-10-06 | 2024-03-21 | 단국대학교 천안캠퍼스 산학협력단 | 이온이 담지된 생활성 유리 나노입자 및 이의 제조방법 |
CN116875550B (zh) * | 2023-09-08 | 2023-12-26 | 天津市肿瘤医院(天津医科大学肿瘤医院) | 一种FABP4+C1q+巨噬细胞及其制备方法和用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005200419A (ja) * | 2004-01-16 | 2005-07-28 | National Health Research Inst | 癌治療法 |
JP2005343802A (ja) * | 2004-05-31 | 2005-12-15 | Norifumi Sakayama | 非ステロイド性消炎鎮痛剤の外用剤を用いた癌細胞の増殖を抑制する方法 |
JP2006501136A (ja) * | 2002-01-14 | 2006-01-12 | ファルマシア・コーポレーション | ペルオキシソーム増殖剤応答性受容体−γアゴニストおよびシクロオキシゲナーゼ−2選択的阻害薬を含む治療用組成物および方法 |
WO2008026729A1 (fr) | 2006-09-01 | 2008-03-06 | National University Corporation Chiba University | Agent thérapeutique pour une synovite villonodulaire pigmentée ou une tumeur à cellules géantes de la gaine tendineuse ou de l'os |
JP2009533467A (ja) * | 2006-04-11 | 2009-09-17 | スミスクライン・ビーチャム・コーポレイション | Pi3キナーゼ阻害剤としてのチアゾリジンジオン誘導体 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06192084A (ja) | 1992-06-30 | 1994-07-12 | Kaken Pharmaceut Co Ltd | 癌転移抑制剤 |
US5753702A (en) | 1996-05-22 | 1998-05-19 | University Of Vermont | Arachidonic acid metabolite, 16-hete |
US6797708B2 (en) | 2001-12-03 | 2004-09-28 | Wyeth | Inhibitors of cytosolic phospholipase A2 |
US7605156B2 (en) | 2001-12-03 | 2009-10-20 | Wyeth | Methods for the use of inhibitors of cytosolic phospholipase A2 |
US7101875B2 (en) * | 2001-12-03 | 2006-09-05 | Wyeth | Methods for treating arthritic disorders |
US6984735B2 (en) | 2001-12-03 | 2006-01-10 | Wyeth | Process for making an aldehyde |
US7713964B2 (en) | 2001-12-03 | 2010-05-11 | Wyeth Llc | Methods for treating asthmatic conditions |
US6635771B2 (en) | 2001-12-03 | 2003-10-21 | Wyeth | N-benzhydryl indole compounds |
DE10237571A1 (de) * | 2002-08-13 | 2004-02-26 | Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin | Endovaskuläres Implantat mit aktiver Beschichtung |
JP2006526652A (ja) | 2003-06-03 | 2006-11-24 | ベス・イスラエル・ディーコニス・メディカル・センター | 血管狭窄を治療するための方法及び化合物 |
JP2007015930A (ja) * | 2004-09-13 | 2007-01-25 | Ono Pharmaceut Co Ltd | 複素ビシクロ環および複素トリシクロ環化合物およびその医薬 |
US20070232586A1 (en) | 2004-04-21 | 2007-10-04 | Kazuyuki Ohmoto | Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof |
JP4179219B2 (ja) | 2004-05-14 | 2008-11-12 | 松下電器産業株式会社 | 電気湯沸かし器 |
US7250550B2 (en) | 2004-10-22 | 2007-07-31 | Wright Medical Technology, Inc. | Synthetic bone substitute material |
KR100753480B1 (ko) * | 2006-01-27 | 2007-08-31 | 씨제이 주식회사 | 잘토프로펜 함유 서방성 정제 및 그 제조방법 |
CA2680212A1 (en) | 2007-03-07 | 2008-09-12 | Janssen Pharmaceutica N.V. | Substituted phenoxy aminothiazolones as estrogen related receptor-.alpha. modulators |
AU2008222745A1 (en) | 2007-03-07 | 2008-09-12 | Janssen Pharmaceutica N.V. | Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
TW200902507A (en) | 2007-03-07 | 2009-01-16 | Janssen Pharmaceutica Nv | Substituted phenoxy n-alkylated thiazolidinediones as estrogen related receptor-α modulators |
CA2721608A1 (en) | 2008-04-15 | 2009-10-22 | Etex Corporation | Minimally invasive treatment of vertebra (mitv) using a calcium phosphate combination bone cement |
KR20110039548A (ko) * | 2008-07-02 | 2011-04-19 | 넥스트21 케이 케이 | 칼슘 이온 용출을 제어한 인공 골재료 |
RU2012130439A (ru) | 2009-12-18 | 2014-01-27 | Др Редди'З Лабораториз, Лимитед | Композиция балаглитазона и способы ее применения |
JP2013519730A (ja) | 2010-02-17 | 2013-05-30 | ヤンセン ファーマシューティカ エヌ.ベー. | エストロゲン関連受容体α変調剤としてのアミノチアゾロン |
CA2789753A1 (en) | 2010-02-17 | 2011-08-25 | Janssen Pharmaceutica Nv | Aminothiazolones as estrogen related receptor-alpha modulators |
WO2011149841A1 (en) | 2010-05-25 | 2011-12-01 | Janssen Pharmaceutica Nv | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS |
WO2013146435A1 (ja) | 2012-03-26 | 2013-10-03 | 日本ケミファ株式会社 | 骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤 |
KR20220000993A (ko) | 2013-09-25 | 2022-01-04 | 닛뽕 케미파 가부시키가이샤 | 골·연부에 발생하는 거세포성 종양, 연골육종 또는 골육종의 예방, 치료 또는 전이 예방을 위한 약제, 동맥색전술용 국소 주입제 및 인공골 |
US9907882B2 (en) | 2014-04-18 | 2018-03-06 | Warsaw Orthopedic, Inc. | Demineralized bone matrix with improved osteoinductivity |
-
2013
- 2013-03-18 WO PCT/JP2013/057706 patent/WO2013146435A1/ja active Application Filing
- 2013-03-18 NZ NZ700872A patent/NZ700872A/en not_active IP Right Cessation
- 2013-03-18 AU AU2013238126A patent/AU2013238126C1/en not_active Ceased
- 2013-03-18 KR KR1020147029881A patent/KR102199273B1/ko active IP Right Grant
- 2013-03-18 US US14/387,981 patent/US10660882B2/en not_active Expired - Fee Related
- 2013-03-18 CA CA2868311A patent/CA2868311C/en active Active
- 2013-03-18 JP JP2014507736A patent/JP5865995B2/ja active Active
- 2013-03-18 EP EP13769796.7A patent/EP2832367B1/en active Active
- 2013-03-18 SG SG11201406032TA patent/SG11201406032TA/en unknown
- 2013-03-18 CN CN201380016296.XA patent/CN104302322A/zh active Pending
- 2013-03-18 CN CN201610647601.0A patent/CN106267210A/zh active Pending
-
2015
- 2015-05-06 HK HK15104298.4A patent/HK1203818A1/xx unknown
- 2015-12-25 JP JP2015252893A patent/JP6205403B2/ja not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006501136A (ja) * | 2002-01-14 | 2006-01-12 | ファルマシア・コーポレーション | ペルオキシソーム増殖剤応答性受容体−γアゴニストおよびシクロオキシゲナーゼ−2選択的阻害薬を含む治療用組成物および方法 |
JP2005200419A (ja) * | 2004-01-16 | 2005-07-28 | National Health Research Inst | 癌治療法 |
JP2005343802A (ja) * | 2004-05-31 | 2005-12-15 | Norifumi Sakayama | 非ステロイド性消炎鎮痛剤の外用剤を用いた癌細胞の増殖を抑制する方法 |
JP2009533467A (ja) * | 2006-04-11 | 2009-09-17 | スミスクライン・ビーチャム・コーポレイション | Pi3キナーゼ阻害剤としてのチアゾリジンジオン誘導体 |
WO2008026729A1 (fr) | 2006-09-01 | 2008-03-06 | National University Corporation Chiba University | Agent thérapeutique pour une synovite villonodulaire pigmentée ou une tumeur à cellules géantes de la gaine tendineuse ou de l'os |
Non-Patent Citations (28)
Title |
---|
"Enzyme Immunoassay", 1978, IGAKU-SHOIN |
"Enzyme Immunoassay", 1982, IGAKU-SHOIN |
"Enzyme Immunoassay", 1987, IGAKU-SHOIN |
"Immunochemical Techniques (Part D: Selected Immunoassays", vol. 84 |
"Immunochemical Techniques (Part E: Monoclonal Antibodies and General Immunoassay Methods", vol. 92 |
"METHODS IN ENZYMOLOGY", vol. 121, ACADEMIC PRESS |
"Methods in ENZYMOLOGY", vol. 70 |
"METHODS IN ENZYMOLOGY", vol. 73 |
"METHODS IN ENZYMOLOGY", vol. 74 |
"Molecular Cloning" |
"Radioimmunoassay", 1974, KODANSHA |
"Radioimmunoassay, Second Series", 1979, KODANSHA |
AKIHIKO TAKEUCHI ET AL.: "Kotsukyo Saiboshu ni Taisuru PPARy (peroxisome proliferator- activated receptor y) Kasseika ni yoru Ko-Shuyo Koka", THE JOURNAL OF THE JAPANESE ORTHOPAEDIC ASSOCIATION, vol. 86, no. 8, 25 August 2012 (2012-08-25), pages S1319, XP008174894 * |
AOKI ET AL., CERAMICS, vol. 10, 1975, pages 469 |
BIOCHEM. PHARMACOL., vol. 82, 2011, pages 464 - 475 |
BULL. INST. CHEM. RES. KYOTOUNI., vol. 60, 1982, pages 260 |
CANCER LETT., vol. 297, 2010, pages 65 - 74 |
EXP. OPIN. THER. PATENTS, vol. 6, no. 5, 1996, pages 441 - 456 |
FEBS LETT., vol. 455, 1999, pages 135 - 139 |
HENCH ET AL., BIOMED. MASTER. SYMP., vol. 2, 1972, pages 117 |
J. PHARMACOL. EXP. THER., vol. 302, 2002, pages 18 - 25 |
J. SAMBROOK ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LAB. PRESS |
JPN. J. CANCER RES., vol. 90, 1999, pages 75 - 80 |
LIU, Y. ET AL.: "Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375", MED ONCOL, vol. 23, no. 3, 2006, pages 393 - 402, XP055168750 * |
MOL. PHARMACOL., vol. 72, 2007, pages 674 - 685 |
NISHIDA, K. ET AL.: "Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor- gamma", BR J CANCER, vol. 86, no. 8, 2002, pages 1303 - 9, XP055168739 * |
VAISH, V. ET AL.: "The role of NF-KB and PPARy in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors", TUMOR BIOL, vol. 31, no. 5, 2010, pages 427 - 36, XP055168743 * |
XIE, K. H. ET AL.: "Rosiglitazone and ATRA on gastric cancer SGC7901 cell line proliferation in vitro", ZHONGGUO YISHI ZAZHI, vol. 12, no. 6, 2010, pages 743 - 7, XP008174893 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10653667B2 (en) | 2013-09-25 | 2020-05-19 | Nippon Chemiphar Co., Ltd | Drug for preventing, treating or preventing metastasis of giant cell tumor that occurs in bone or soft parts, chondrosarcoma, or osteosarcoma, local injection for arterial embolization, and artificial bone |
JP2016540044A (ja) * | 2013-11-18 | 2016-12-22 | 中国医学科学院生物医学工程研究所Institute Of Biomedical Engineering, Chinese Academy Of Medical Science | 新規な抗hpv医薬製剤の用途 |
US10045954B2 (en) | 2013-11-18 | 2018-08-14 | Institute Of Biomedical Engineering, Chinese Academy Of Medical Science | Use of novel anti-HPV pharmaceutical preparation |
JP2018501254A (ja) * | 2014-12-22 | 2018-01-18 | ファイヴ プライム セラピューティクス インク | Pvnsを治療するための抗csf1r抗体 |
JP2018536011A (ja) * | 2015-12-01 | 2018-12-06 | テリアカ バイオメディカル インコーポレイテッドTheriac Biomedicale Inc. | PPARγ活性化剤とその使用 |
Also Published As
Publication number | Publication date |
---|---|
AU2013238126A1 (en) | 2014-11-06 |
CN104302322A (zh) | 2015-01-21 |
JP5865995B2 (ja) | 2016-02-17 |
EP2832367B1 (en) | 2020-07-15 |
KR20140139070A (ko) | 2014-12-04 |
CA2868311C (en) | 2021-06-22 |
AU2013238126B2 (en) | 2017-12-21 |
AU2013238126C1 (en) | 2018-06-14 |
CN106267210A (zh) | 2017-01-04 |
KR102199273B1 (ko) | 2021-01-06 |
EP2832367A1 (en) | 2015-02-04 |
JP2016102129A (ja) | 2016-06-02 |
US10660882B2 (en) | 2020-05-26 |
US20150045396A1 (en) | 2015-02-12 |
JPWO2013146435A1 (ja) | 2015-12-10 |
EP2832367A4 (en) | 2015-12-16 |
SG11201406032TA (en) | 2014-11-27 |
NZ700872A (en) | 2016-09-30 |
JP6205403B2 (ja) | 2017-09-27 |
CA2868311A1 (en) | 2013-10-03 |
HK1203818A1 (en) | 2015-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6205403B2 (ja) | 骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤 | |
Liu et al. | Osteoclasts protect bone blood vessels against senescence through the angiogenin/plexin-B2 axis | |
Oñate et al. | Stem cells isolated from adipose tissue of obese patients show changes in their transcriptomic profile that indicate loss in stemcellness and increased commitment to an adipocyte-like phenotype | |
Antonov et al. | Regulation of macrophage foam cell formation by αVβ3 integrin: potential role in human atherosclerosis | |
Lim et al. | Dual function of Bmpr1a signaling in restricting preosteoblast proliferation and stimulating osteoblast activity in mouse | |
US20140274766A1 (en) | Methods of using f-spondin as a biomarker for cartilage degenerative conditions and bone diseases | |
US20100222438A1 (en) | Methods compositions and article of manufacture for modulating bone growth | |
Dong et al. | Melatonin induces osteoblastic differentiation of mesenchymal stem cells and promotes fracture healing in a rat model of femoral fracture via neuropeptide Y/neuropeptide Y receptor Y1 signaling | |
US9802994B2 (en) | Composition for preventing or treating fracture or osteoporosis using slit-robo system | |
Yamada et al. | RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression | |
Scheiber et al. | 4PBA reduces growth deficiency in osteogenesis imperfecta by enhancing transition of hypertrophic chondrocytes to osteoblasts | |
Zhu et al. | Cortical bone is an extraneuronal site of norepinephrine uptake in adult mice | |
Fujisawa et al. | CCN family 2/connective tissue growth factor (CCN2/CTGF) stimulates proliferation and differentiation of auricular chondrocytes | |
Ge et al. | The secreted protein WNT5A regulates condylar chondrocyte proliferation, hypertrophy and migration | |
Nakamura et al. | Pigment Epithelium-Derived Factor (PEDF) mediates cartilage matrix loss in an age-dependent manner under inflammatory conditions | |
Kosugi et al. | Disruption of the aldehyde dehydrogenase 2 gene increases the bone anabolic response to intermittent PTH treatment in an ovariectomized mouse model | |
JP2010189302A (ja) | 病変間葉系幹細胞が関連する疾患の治療剤および間葉系幹細胞の検出マーカーの利用 | |
JP6527822B2 (ja) | 骨・軟部に発生する巨細胞性腫瘍、軟骨肉腫または骨肉腫の予防、治療または転移の予防のための薬剤、動脈塞栓術用局所注入剤、および、人工骨 | |
Li et al. | Schnurri-3 controls osteogenic fate of Adipoq-lineage progenitors in bone marrow | |
Neag | Targeting the novel CD248-MMRN2-CLEC14A pathway in age-related bone loss | |
Dai | Osteopontin Secreted by Macrophages in Epididymal Fat Tissue Regulates Bone Homeostasis through Activation of Macrophages in Bone Marrow in Mice | |
Pu et al. | Expression and significance of protein-degrading enzymes in cartilage and subchondral bone in osteoarthritis | |
Sun et al. | lncTIM3 promotes osteogenic differentiation of bone marrow mesenchymal stem cells via miR-214/Smad4 axis to relieve postmenopausal osteoporosis | |
Li et al. | YBX1 promotes type H vessel–dependent bone formation in an m5C-dependent manner | |
POPULATIONS-AN | USING FRACTURE RISK ASSESSMENT TOOLS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13769796 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014507736 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2868311 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14387981 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013769796 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20147029881 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013238126 Country of ref document: AU Date of ref document: 20130318 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |